- 10 providers seeking RCM talent
- How the PeaceHealth physician dispute became a national test for corporate medicine
- 12 health systems with credit rating upgrades
- Could autism care benefit from more therapy choices?
- 4 hospital CFOs becoming CEOs
- Kaiser Permanente’s operating margin slips to 2.1% in Q1
- Prime acquires 55th hospital
- MedicusOne: A More Strategic Approach to Locum Tenens Management
- How health systems can validate ROI and scale ambient AI
- Staffing, stewardship and AI: 5 resources for healthcare leaders
- The Medical Device Cybersecurity Gap Hiding in Plain Sight
- The Medical Device Cybersecurity Gap Hiding in Plain Sight
- Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan
- As Ranks of Uninsured Grow, Minnesota’s Hospitals Are Among Least Charitable in Nation
- Watch: 8 Health Insurance Terms You Should Know
- OVID Health hires Edelman alum Davide Scalenghe to boost its international footprint
- Maintaining trust in medical AI: Monitoring and managing model lifecycle
- Maintaining trust in medical AI: Monitoring and managing model lifecycle
- Eli Lilly shoots for health in new Caitlin Clark ad campaign
- Omada Health posts 42% revenue jump in Q1, joins Eli Lilly employer weight loss program
- Journalists Shed Light on Deadly Hantavirus Outbreak and a Crisis in the Nation’s ERs
- Is the horizon still bright for orthodontists?
- The Make America Healthy Again Movement Comes for Hospital Food
- What’s driving physicians to early retirement
- Why Tenet’s CEO says ASCs keep choosing USPI
- Hospitals embrace rapid opioid treatment in fentanyl era: Study
- Texas systems open 200-bed behavioral health center
- Lone Peak Dental Group acquires Arizona practice
- Inside Northwestern Medicine’s battle against surgeon burnout
- Tennessee optometrist pleads guilty to $6.9M Medicare fraud
- Surgery Partners doubles down on orthopedics, robotics as total joint growth hits 14.6%
- The growing war over Anthem’s out-of-network penalty policy
- 3 PDS Health headlines to know in 1 week
- Remarks at the Conference on Financial Market Regulation
- Could ASCs help cardiology move past its ‘breaking point’?
- 3 programs expanding the anesthesia workforce in 2026
- Dad Jokes: Remarks at the 13th Annual Conference on Financial Markets Regulation
- UVM Health targets $300M in cuts, outpatient overhaul amid $280M deficit
- Maine behavioral health provider cites industry pressures in merger
- Dentists opening practices in 1 month
- The Aspen Group names new chief commercial officer
- RFK Jr. Launches Plan To Curb Antidepressant 'Overprescription'
- Georgia mental health provider adds after-hours outpatient program
- AI-augmented behavioral health provider Theris launches out of stealth
- 5 data breaches, settlements impacting cardiology
- Maine hospital adds stroke prevention, cardiac imaging services
- As new tech, AI sweeps the marketing world, Eversana Intouch’s new CEO is ‘comfortable in the gray’
- Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M
- Trump plans to fire FDA chief Marty Makary: report
- Trump plans to fire FDA chief Marty Makary: report
- Oregon governor signs behavioral health workforce expansion bills amid shortage
- Remarks at the Special Competitive Studies Project AI+ Expo
- Lawmakers, former FDA leaders and more rally behind mifepristone as Supreme Court weighs telemedicine access to abortion pill
- 5 DSOs making headlines
- Plant-Based Foods May Help Lower Risk of High Blood Pressure
- The ACA exchanges dominated Q1 earnings calls. Here's what payer, health system execs had to say
- Integrated CDO capabilities reduce early development complexity
- Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
- Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'
- Workplace safety is a top priority for 93% of healthcare leaders: Axon survey
- Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma
- Op-ed: It's time to make more strategic bets on AI in healthcare
- Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
- Super Shoes Might Increase Risk Of Running Injuries, Study Says
- TV, Movies Offer Flawed Depictions Of Autism, Add To Delayed Diagnosis, Study Says
- Opioid OD Survivors Have Triple Rate Of Repeat Overdoses Than Previously Estimated
- Revisiting Pharma’s tariff reality
- A New Medicare Option For Weight Loss Drugs: What Older Americans Should Know
- Exposure Therapy Can Successfully Ease Peanut Allergies
- In California Governor Race, Single-Payer Is a Litmus Test. There’s Still No Way To Pay for It.
- Listen: A Federal Agency Is After Workers’ Health Data, and Critics Are Alarmed
- AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard
- Johnson & Johnson launches ‘Generation Fine’ depression project
- Pre-launch efforts linked to lasting drug awareness edge: report
- GSK tees up a Modern Family for meningitis messaging
- NYC invests $12M in overdose recovery workforce
- Aspen Dental to pay $2M to settle allegations of violating corporate dentistry laws
- Texas dental practice relocates into 6K-square-foot facility
- Medit launches global orthodontics division, acquires California training institute
- Pennsylvania enacts dental faculty bill
- Cruise Ship Hantavirus Outbreak Kills 3 as WHO Says Risk Is Low
- How policy, reimbursement incentives, could help healthcare address its climate footprint
- Remarks at the 13th Annual Conference on Financial Market Regulation
- 5 best practices for financially integrating behavioral health
- Fierce Pharma Asia—Summit’s surprise interim trial miss; UCB’s $2B Candid buy; J&J’s CAR-T cuts
- Amazon Pharmacy to offer home delivery for Novo Nordisk's Ozempic pill
- New York expands behavioral health data access in EHRs
- Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
- New Hampshire to receive $29.5M in Purdue opioid settlement
- Clover Health's MA membership grows 51% year-over-year
- New Study Suggests The Brain Can Continue Learning While In An Unconscious State
- Health Tech Weekly Rundown: Tether rolls out medical AI for phones, wearables; Medaptus launches operational ‘command center’
- Pennsylvania sues Character.ai over AI chatbot allegedly presenting itself as licensed medical professional
- Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
- FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
- Every 1,000 Steps After Surgery Cuts Complication Risk, Study Finds
- Bullying and Politics Fuel Suicide Risk for LGBTQ+ Teens and Young Adults, Survey Finds
- Head Impacts May Disrupt Gut Health Even Without Concussion
- Class of Migraine Drug, CGRP Inhibitors, Has Added Benefit: Reduced Glaucoma Risk
- States Eye Aid to Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
- That Discount at the Pharmacy Counter May Pack Hidden Costs
- Hims & Hers debuts its first AI care agent to interpret biomarker lab results
- Alnylam rebuked by FDA over efficacy claims on Amvuttra website
- Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive
- Oscar Health's profit hits $679M, membership rises in Q1
- Joint Commission, NACHC partner on training, new accreditation for community health centers
- Ardent Health touts outpatient growth, checked labor spend during hectic Q1
- FDA Authorizes Fruit-Flavored Vapes for Adults
- Nearly 8 in 10 employers say GLP-1 coverage drives up benefit costs: Business Group on Health
- Edibles + Alcohol Combo Poses Driving Risks Missed by Sobriety Tests
- Leapfrog Group's latest safety grades have far fewer low scores since removal of non-participating hospitals
- VR Training Helps Autistic People Navigate Police Encounters
- Weight Loss Surgeries Fall More Than 20% As Patients Turn To GLP-1 Meds, Experts Say
- Amwell boasts higher than expected renewals, retention despite Q1 revenue decline
- First Psych Ward Stay Signals Long-Term Mental Health Struggles For Nearly All Patients
- Why Melatonin Shouldn't Be A Bedtime Go-To For Kids
- Children Living Near Gas Stations Have Higher Cancer Risk, Study Finds
- The timing is right for psychedelics manufacturer Optimi Health's IPO
- HHS' Healthy Food Agenda Puts Hospitals On Notice About Patients' Meals
- Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
- Inside the gaps in fertility and surrogacy systems
- CVS execs say company on track to meet MA margin goals by 2028
- Facilitating Access to Trump Accounts
- Fixing Failures to Communicate
- Hinge Health lifts 2026 outlook after strong Q1 as it expands to new conditions
- Supreme Court Issues Stay, Keeping Abortion Pill Mifepristone Available by Mail For Now
- Statement on Proposing Release for Semiannual Reporting
- Quarterly Questions: Statement on the Proposed Amendments to Allow Semiannual Reporting
- Statement on Proposing Semiannual Reporting
- Newer Migraine Drugs Reduce Headache Days With Fewer Side Effects
- New Drug Combo Effective Against Treatment-Resistant IBD, Trials Show
- New Warning Labels Might Help People Cut Back On Drinking
- Ozempic Can Curb Cravings in Alcohol Use Disorder, Landmark Trial Finds
- US on the Brink of Losing Measles-free Status, Study Warns
- Delays in Visa Program Threaten Doctor Placements in Underserved Areas
- Supreme Court Puts Brakes on Abortion Pill Restrictions
- FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib
- Online Misinformation Adding To Americans' Skin Cancer Risk, Survey Finds
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Social Media Videos, Easy Access Raise Risk of Teen Inhalant Use
- Staff Statement Regarding Pooled Employer Plans
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- 'Fitspirational' Posts Can Be More Harmful Than Motivational, Review Concludes
- Parents’ Stress Tied to Children’s Mental Health, New Survey Finds
The breath-taking extent to which health insurance interferes between patient and clinician comes to life in this Associated Press documentary.
Photo library clipped due to length, but remains available at the link.
Limits to anti-nausea pill coverage wear on cancer patients and doctors
Cancer patients can ward off waves of vomiting after treatment with a relatively cheap anti-nausea pill, but some are running into coverage limits.
Doctors say restrictions on the number of tablets patients receive can hurt care. Pharmacy benefit managers say their limits guard against overuse, and they offer workarounds to get more tablets.
In between sit patients, who might ration pills or opt for less effective help for a dreaded side effect of radiation or chemotherapy.
The conflict shows how an array of coverages and poor communication can complicate even simple acts of care in the fragmented U.S. health care system.“This is sort of the dirty underbelly of the current health care environment,” said oncologist Dr. Fumiko Chino. “Insurance companies and pharmacy benefit managers are somehow weirdly ending up in my exam room, standing between me and my patients.”
Steven Manetta takes at least a half dozen pills daily to help keep a form of leukemia in remission. For more than a year, he rationed his go-to anti-nausea pill, ondansetron, known by the brand-name Zofran.
Manetta’s coverage through CVS Caremark paid for 18 ondansetron pills every 21 days. That forced him to sometimes use alternatives that make him extremely drowsy in order to stretch his supply. He only recently got approval for a 90-day supply.
“It’s just like an extra thing to think about all the time,” the 33-year-old Lemont, Illinois, resident said. “When you’re on so many medications, the ones with the least side effects are the ones you always want to reach for.”
Ondansetron hit the U.S. market more than 30 years ago. It was the first in a series of drugs that gave doctors a better way to control nausea and vomiting, said Dr. Alexi Wright, a Dana-Farber Cancer Institute oncologist who teaches at Harvard.
Wright and other cancer specialists call ondansetron a cornerstone treatment because of its relative safety, effectiveness and limited side effects.
The price doesn’t hurt either: Thirty tablets of ondansetron can cost under $12 through prescription discount websites.
Pharmacists and doctors say they’ve dealt with restrictions on anti-nausea drugs like ondansetron for years. Wright says she finds the limits “infuriating” in part because the drug is affordable.
More than half the plans sold on the U.S. individual insurance marketplace limit the number of ondansetron tablets that patients can get, according to preliminary results from a study by Chino and Michael Anne Kyle, a University of Pennsylvania researcher.
Pharmacist Yen Nguyen frequently sees these restrictions, including the limits from CVS Caremark that Manetta encountered.
“Over four or five months of chemotherapy, you’re fighting for dimes and nickels here,” said Nguyen, executive director of pharmacy for the Houston-area practice Oncology Consultants.
Jennette Murphy paid cash for ondansetron when her cancer treatment started earlier this year because she couldn’t get coverage for the amount her doctor requested. Then she got a letter telling her the drug wouldn’t be covered.
“It freaked me out,” the Tehachapi, California, resident said. “I’m like, ‘Really? Have you ever been through chemo?’”
Pharmacy benefit managers say they set limits based partly on the treatment and offer several ways for doctors to request more.
Prime Therapeutics limits 4- and 8-milligram prescriptions of ondansetron to 21 tablets over 30 days. That helps provide “maximum dosing” for seven days of treatment a month, chief clinical officer David Lassen said in an email.
He said quantity limits are approved by independent doctors and pharmacists. They help prevent waste and excessive use that may not be safe.
CVS Caremark spokesman Mike DeAngelis said his company bases limits on Food and Drug Administration guidelines. He added that the company can make a decision on requests for more tablets in less than 24 hours.
Doctors say they don’t always know when patients will need more.
Coverage limits vary, and some patients may not tell their doctor that they got a smaller-than-desired amount. Also, nausea intensity can be hard to gauge with newer treatments.
Chino says she wants patients to start with 90 tablets of ondansetron, enough to take the drug three times a day for a month if needed. But she often sees limits of 21 or 30 tablets.
“The fact that there’s still restrictive patterns on this very useful medication is insane,” said Chino, who recently moved from Memorial Sloan Kettering in New York to MD Anderson in Houston.
Limits can hurt patients who have big copayments for each refill or trouble getting to the drugstore, noted Dr. Ramy Sedhom, an oncologist and palliative care specialist with Penn Medicine Princeton Health.
“I have a lot of patients who only go to the pharmacy once a month when their niece or nephew is in town to pick up the (prescriptions),” he said.
If patients run out of ondansetron, even for a few days, uncontrolled vomiting can send them to emergency rooms or force a treatment pause, doctors say.
Murphy, the cancer patient, has avoided all of that. She said coverage started for ondansetron after her City of Hope cancer center doctor requested it.
She faces a stretch of chemotherapy cycles that will extend well into the fall. The treatments leave her bedridden for days with nausea even while taking ondansetron.
“I would hate to not have it,” she said.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.














